stockrow
Friday 6 November 2026
Export SOLV’s income statement to Excel — free account
Solventum Corporation
SOLV Healthcare Medical Instruments & Supplies
Solventum Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.86% from fiscal 2024.
- Revenue
- −7.01%
- EPS
- −101.0%
- Free cash flow
- +561.9%
- Total debt
- −90.1%
Quarter to September 2026, against a year earlier
87.18
2.17
−2.43%
Follow SOLV
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
8.87 | 7.95 | 9.39 | 99.04 |
P/S ratio |
1.66 | 1.38 | 1.60 | 1.84 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
145.22 | (60.19) | 58.70 | 85.06 | |
P/B ratio |
2.73 | 2.29 | 2.78 | 3.13 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.17 | 1.95 | 2.19 | 2.44 | |
EV/EBITDA |
6.76 | 6.18 | 7.05 | 7.70 | |
EV/Operating CF |
48.92 | 106.63 | 87.11 | 64.17 | |
EV/FCF |
(1,805.27) | (79.32) | (154.29) | 0.00 | |
Quick Ratio |
0.66 | 0.52 | 0.50 | 0.52 | |
Current Ratio |
1.23 | 1.07 | 1.02 | 1.03 | |
Net Debt/EBITDA |
17.18 | 21.98 | 15.55 | 0.00 | |
Debt/Assets |
35.22% | 37.50% | 37.11% | 3.58% | |
Debt/Equity |
1.00 | 1.06 | 1.10 | 0.11 | |
Asset Turnover |
0.58 | 0.58 | 0.57 | 0.58 | |
Operating CF/Net income |
1.51 | (14.54) | 2.47 | (14.75) | |
Capex/Depreciation |
(0.54) | (0.62) | (0.62) | (0.59) | |
Interest Coverage |
2.45 | 1.29 | 2.83 | 0.00 | |
Research and Development Expense of Revenue |
8.71% | 9.42% | 8.06% | 9.29% | |
Selling, General and Administrative Expense of Revenue |
37.99% | 41.21% | 41.96% | 41.71% | |
Intangible Assets out of Total Assets |
0.58 | 0.58 | 0.56 | 0.56 | |
Share Based Compensation of Revenue |
1.85% | 2.54% | 1.72% | 2.15% | |
Graham Net Nets |
(0.39) | (0.49) | (0.43) | (0.38) | |
Graham Number |
76.34 | 72.60 | 71.69 | 23.74 | |
Earnings Yield |
11.27% | 12.57% | 10.65% | 1.01% | |
Free Cash Flow Yield |
(0.07%) | (1.78%) | (0.89%) | 0.00% | |
Revenue per Share |
11.48 | 11.52 | 12.79 | 11.41 | |
Operating CF per Share |
0.55 | (1.08) | 1.31 | 1.04 | |
Capex per Share |
(0.36) | (0.48) | (0.48) | (0.47) | |
Free Cash Flow per Share |
0.18 | (1.57) | 0.83 | 0.57 | |
Cash per Share |
5.04 | 3.22 | 2.33 | 2.64 | |
Shareholders Equity per Share |
29.00 | 28.52 | 27.79 | 28.13 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
29.00 | 28.52 | 27.79 | 28.13 | |
Free Cash Flow |
32.00 | (273.00) | 144.00 | 97.00 | |
Working Capital |
723.00 | 237.00 | 78.00 | 117.00 | |
Capital Expenditures |
(63.00) | (84.00) | (83.00) | (80.00) | |
Net Current Asset Value |
(5,386.00) | (5,545.00) | (5,702.00) | (5,668.00) | |
EV/EBIT |
8.28 | 7.63 | 8.77 | 9.58 | |
Capex to Sales |
0.03 | 0.04 | 0.04 | 0.04 | |
Price to Operating Income |
6.33 | 5.39 | 6.42 | 7.25 | |
| Other line items | |||||
Average Receivables |
1,206.50 | 1,145.50 | 1,343.50 | 1,283.50 | |
Average Payables |
652.50 | 651.50 | 672.00 | 738.50 | |
Average Inventory |
1,015.50 | 977.50 | 1,001.00 | 1,075.50 | |
Average Assets |
14,375.50 | 14,312.00 | 14,658.50 | 14,069.00 | |
Average Common Equity |
4,004.50 | 4,116.00 | 4,222.00 | 4,895.50 |
Columns are period end dates · fundamentals updated 5 Nov 2026